{
    "clinical_study": {
        "@rank": "130951", 
        "arm_group": {
            "arm_group_label": "Neratinib", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive neratinib PO daily on days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how\n      HER2 mutated cancer responds to treatment with neratinib."
        }, 
        "brief_title": "Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria for Pre-registration:\n\n          -  Histologically or cytologically confirmed HER2-negative (0 or 1+ by IHC or\n             non-amplified by FISH) breast cancer that is stage IV.\n\n          -  There is no limitation on the number of prior lines of systemic therapy.\n\n          -  Presence of measurable or non-measurable disease by RECIST 1.1.\n\n          -  At least 18 years of age.\n\n          -  ECOG performance status < or = 2.\n\n          -  Adequate organ function as defined below within 8 weeks of pre-registration:\n\n               -  Serum creatinine < or = 1.5 x ULN\n\n               -  Total bilirubin < or = 1.5 x ULN )in case of known Gilbert's syndrome, < 2 x ULN\n                  is allowed)\n\n               -  AST and ALT < or = 3 x ULN\n\n          -  Able to understand and willing to sign an IRB approved written informed consent\n             document.\n\n        Note: HER2 mutation testing may be performed while the patient is receiving active\n        systemic therapy for metastatic breast cancer so that the result can be used to determine\n        eligibility for study drug therapy in the future.\n\n        Exclusion Criteria for Pre-registration:\n\n          -  Testing for LVEF is not required for pre-registration, but patient must not have a\n             recent LVEF < LLN or have symptoms of congestive heart failure.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric\n             illness/social situations that would limit compliance with study requirements.\n\n          -  Acute or currently active hepatic or biliary disease requiring antiviral therapy\n             (with the exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases,\n             or stable chronic liver disease per investigator assessment).\n\n          -  History of significant cardiac disease, cardiac risk factors, or uncontrolled\n             arrhythmias.\n\n          -  Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs\n             resulting in dyspnea at rest.\n\n        Inclusion Criteria for Registration\n\n          -  Tumor tissue tested positive for HER2 mutation.\n\n          -  ECOG performance status < or = 2.\n\n          -  Adequate organ function as defined below within 2 weeks of registration:\n\n               -  ANC > or = 1.5 x 10^9/L\n\n               -  Platelet count > or = 100 x 10^9/L\n\n               -  Serum creatinine < or = 1.5 x ULN\n\n               -  Total bilirubin < or = 1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN\n                  is allowed)\n\n               -  AST and ALT < or = 3 x ULN\n\n          -  The patient must have completed radiation therapy and be at least 1 week from the\n             last systemic chemotherapy administration, with adequate recovery of bone marrow and\n             organ functions, before starting neratinib.\n\n          -  Presence of disease progression on the most recent disease evaluation.\n\n          -  Patients with known brain metastasis are eligible, but must have received radiation\n             and be off steroids and stable (without evidence of disease progression by imaging or\n             exam) for 3 months.\n\n          -  QTc interval < or = 0.450 seconds within 2 weeks of registration.\n\n          -  LVEF > or = institutional ILLN within 4 weeks of registration.\n\n          -  Women of childbearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control, abstinence) prior to study entry and\n             for the duration of study participation.  Should a woman become pregnant or suspect\n             she is pregnant while participating in this study, she must inform her treating\n             physician immediately\n\n          -  Able to understand and willing to sign an IRB approved written informed consent\n             document.\n\n          -  There is no limitation on the number of prior lines of systemic therapy.\n\n        Exclusion Criteria for Registration:\n\n          -  Currently receiving any other investigational agents or systemic cancer therapy.\n\n          -  Currently taking medications and herbal or dietary supplements that are strong\n             cytochrome P450 (CYP) 3A4 inducers or inhibitors.  The washout period must have been\n             completed prior to the start of neratinib if the patient was taking any of these\n             agents.  If unavoidable, patients taking CYP3A4 inhibitors should be monitored\n             closely.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          -  Acute or currently active/requiring antiviral therapy hepatic or biliary disease\n             (with the exception of patients with Gilbert's syndrome, asymptomatic gallstones,\n             liver metastases, or stable chronic liver disease per investigator assessment).\n\n          -  Pregnant and/or breastfeeding.\n\n          -  History of significant cardiac disease, cardiac risk factors, or uncontrolled\n             arrhythmias.\n\n          -  Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs\n             resulting in dyspnea at rest.\n\n          -  Experiencing grade 2 or greater diarrhea."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670877", 
            "org_study_id": "201209135"
        }, 
        "intervention": {
            "arm_group_label": "Neratinib", 
            "intervention_name": "Neratinib", 
            "intervention_type": "Drug", 
            "other_name": "PF-05208767"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": [
            {
                "contact": {
                    "email": "aforero@uab.edu", 
                    "last_name": "Andres Forero-Torres, M.D.", 
                    "phone": "205-975-2837"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Andres Forero, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tripathy@usc.edu", 
                    "last_name": "Debu Tripathy, M.D.", 
                    "phone": "323-865-3962"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University of Southern California"
                }, 
                "investigator": {
                    "last_name": "Debu Tripathy, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mpegram@stanford.edu", 
                    "last_name": "Mark Pegram, M.D.", 
                    "phone": "650-723-5801"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford Medicine Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Mark Pegram, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "melody_cobleigh@rush.edu", 
                    "last_name": "Melody Cobleigh, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Melody Cobleigh, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rachel_freedman@dfci.harvard.edu", 
                    "last_name": "Rachel Freedman, M.D.", 
                    "phone": "617-632-6876"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana-Farber Cancer Institute, Harvard University"
                }, 
                "investigator": {
                    "last_name": "Rachel Freedman, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hayesdf@umich.edu", 
                    "last_name": "Daniel Hayes, M.D.", 
                    "phone": "734-615-6725"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan"
                }, 
                "investigator": {
                    "last_name": "Daniel Hayes, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tpluard@saint-lukes.org", 
                    "last_name": "Timothy J Pluard, M.D.", 
                    "phone": "816-932-6005"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "St. Luke's Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Timothy J Pluard, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cma@dom.wustl.edu", 
                    "last_name": "Cynthia Ma, M.D., Ph.D.", 
                    "phone": "314-362-9383"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": [
                    {
                        "last_name": "Matthew Ellis, MB., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ron Bose, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Shashikant Kulkarni, M.S.., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Michael Naughton, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Steven Sorscher, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Rama Suresh, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Adel Tabchy, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Foluso Ademuyiwa, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dangc@mskcc.org", 
                    "last_name": "Chau Dang, M.D.", 
                    "phone": "646-888-4554"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Shanu Modi, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Chau T Dang, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Lisa_Carey@med.unc.edu", 
                    "last_name": "Lisa Carey, M.D.", 
                    "phone": "919-843-6814"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27514"
                    }, 
                    "name": "University of North Carolina at Chapel Hill"
                }, 
                "investigator": [
                    {
                        "last_name": "Charles Perou, Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Lisa A Carey, M.D.", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kimberly.blackwell@duke.edu", 
                    "last_name": "Kimberly Blackwell, M.D.", 
                    "phone": "919-681-0874"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Kimberly Blackwell, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "erin.olson@osumc.edu", 
                    "last_name": "Erin Macrae, M.D.", 
                    "phone": "614-366-8541"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University"
                }, 
                "investigator": {
                    "last_name": "Erin Macrae, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kgelmon@bccancer.bc.ca", 
                    "last_name": "Karen Gelmon, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 1L3"
                    }, 
                    "name": "BC Cancer Agency"
                }, 
                "investigator": {
                    "last_name": "Karen Gelmon, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "philippe.bedard@uhn.ca", 
                    "last_name": "Philippe Bedard, M.D.", 
                    "phone": "416-946-4534"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Philippe Bedard, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer", 
        "overall_contact": {
            "email": "cma@dom.wustl.edu", 
            "last_name": "Cynthia Ma, M.D., Ph.D.", 
            "phone": "314-362-9383"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Cynthia Ma, M.D., Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).  Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. Eighty percent confidence interval (CI) will be calculated.", 
            "measure": "Overall clinical activity (CR+PR+SD\u22656months) of neratinib in patients with metastatic HER2 breast cancer that carry HER2 mutation", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670877"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The time to progression or death will be listed, and the progression-free survival (PFS) will be estimated using Kaplan-Meier product limit method.  For all the enrolled patients, the number and percentage of patients with HER2 mutation will be presented, and its 95% CI will also be calculated. The agreement for the occurrence of HER2 mutation in paired primary and metastatic sites will be described using contingency tables and assess by McNemar test. The association of the presence of HER2 mutation with histology subtype (invasive lobular vs invasive ductal cancer), tumor grade, tumor staging at initial diagnosis (I vs II or III vs IV), and progression-free survival (PFS) will be assessed using Fisher's exact test, Mann-Whitney rank sum test, or log-rank test as appropriate.", 
                "measure": "PFS of patients treated with neratinib", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Correlate the presence of HER2 mutation with histology subtype (invasive lobular vs. invasive ductal cancer), tumor grade (grade 1-2 vs 3), tumor staging at initial diagnosis (I vs. II or III vs. IV), disease free survival in HER2- breast cancer.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}